Sunday, 28 April 2013

Mitochondrial dysfunction in CFS - the emerging elephant?

The mitochondrion (click to enlarge)
The central symptom in CFS is profound fatigue, yet the origins and mechanisms underlying this fatigue are still contentious. Psychological, sensory/neural and cellular/mitochondrial processes have been considered. Of these the potential role of cellular energy failure and mitochondrial dysfunction has attracted increasing interest and now underpins several metabolic and inflammatory models of CFS 1–4. Mitochondria house the molecular machinery which mediates aerobic energy metabolism in animal cells, enabling the highly efficient oxygen-dependent production of ATP: the major biological energy molecule. Mitochondrial dysfunction therefore provides a powerful explanation for fatigue in CFS. Many findings are now consistent with this rationale and will be briefly reviewed below.

In the muscles
Research into energy metabolism in CFS properly started back in the early-mid ‘90s 5 and has slowly grown and diversified since. Early studies (pre-2000) looked at muscle tissue in CFS. Several of these found evidence of altered energy metabolism in skeletal muscle in response to exercise in CFS patients (for review see 5). Findings included reduced oxidative metabolism, ATP depletion and increased lactate production 6–9. In addition mitochondrial abnormalities and changes to mtDNA were found in CFS muscle tissue 10; while not in another study 11. More recently CFS patients were reported to have altered muscle excitability and increased oxidative stress in response to exercise 12,13. Research by another group further implicates a state of profoundly altered bioenergetic function in CFS patients in response to exercise, including findings of increased acidosis and a co-association between skeletal muscle and cardiac bioenergetic abnormalities 14,15.

In the blood
Recent research into CFS has seen studies assessing mitochondrial function via several blood cell-types. McLaren-Howard and colleagues have found that mitochondrial dysfunction in neutrophils correlates fatigue in CFS 16–18. These studies further implicated altered TL protein function, co-factor insufficiency and toxin accumulation. Peripheral blood mononuclear cells (PBMC) have been used by other teams. An early study on PBMCs from CFS patients found changes in gene expression suggesting perturbed mitochondrial function 19. A later study by another group found that ATP resynthesis was decreased in PBMCs from CFS patients; findings suggested that this was not caused by a defect in the enzyme complexes catalysing oxidative phosphorylation, but in another factor 20. This year another study on PBMCs has reported that ATP and Co-Q10 levels are decreased while lipid peroxidation (i.e. oxidative stress) is increased in CFS (and FM) 21.

In the brain
There is now also evidence for brain energy dysfunction in CFS. Recent in vivo MRSI studies by Shungu et al have found increased cerebral spinal fluid (CSF) lactate in CFS (and MDD) 22–24. Lactate, which can accumulate when aerobic energy metabolism fails, correlated with symptoms of fatigue in CFS. Increased lactate levels also inversely correlated to those of cortical glutathione (GSH), the major cellular antioxidant in the body, thus linking oxidative stress with energy dysfunction in the brain in CFS 24.

Bioenergetic nutrients and cofactors
Other studies assessing nutritional and bioenergetic cofactors have provided further indirect evidence of mitochondrial dysfunction in CFS. Several studies have found lowered blood levels of carnitine derivatives 25–29 and decreased acetyl-carnitine brain uptake in CFS 30; while a couple of other studies failed to find any changes in blood levels 31,32. Low Co-Q10 levels in PBMCs 21 and serum have been reported in CFS 33 and correlate with illness severity 34. Another bioenergetic factor, magnesium, has also been reported to be deficient in CFS 33,35. Supplementation with carnitine 36,37, NADH 38–40 or D-ribose 41,42 had beneficial effects in several studies. Changes to the make-up of the mitochondrial membrane have also been implicated in CFS 43,44, and treatment aimed at restoring membrane integrity (lipid replacement therapy, LRT) significantly decreased fatigue in a small study on CFS patients 44.

There is now substantial evidence to suggest systemic mitochondrial dysfunction occurs in ME/CFS and underlies symptoms of fatigue. The causes of this dysfunction could be many but likely include impaired blood flow, cofactor depletion (e.g. Co-Q10), oxidative damage and dysregulation by inflammatory signaling 1–4. It is further worth noting that mitochondrial dysfunction is also not inconsistent with sensory-related findings in CFS 45–47. New research is desperately required to provide further clarification of the changes to energy metabolism occurring in ME/CFS. Several of the research teams above may release more work in this area this year. For example Dr. Newton and colleagues have more muscle studies in the pipeline. Dr. Shungu and colleges have won a $2 million grant from the NIH to further their brain studies with larger cohorts. To date, research implicating a cellular basis for fatigue in CFS has been poorly covered by mainstream media (including wiki) and is not recognised by public health institutions, as the evidence matures hopefully this will change.

1.         Van Konynenburg, R. A. Glutathione depletion-methylation cycle block: a hypothesis for the pathogenesis of chronic fatigue syndrome. in 8th International IACFS Conference on Chronic Fatigue Syndrome, Fibromyalgia and other Related Illnesses (2007). at
2.         Morris, G. & Maes, M. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab. Brain Dis. 28, 523–40 (2013).
3.         Pall, M. Explaining Unexplained Illnesses: Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others. (New York: Haworth Medical Press, 2007).
4.         Chazotte, B. in Mitochondria in pathogensis (eds. Lemasters, J. J. & Nieminen, A.-L.) 393–410 (Kluwer Academic Publishers, 2002). doi:10.1007/b114376
5.         Chaudhuri, A. & Behan, P. O. In vivo magnetic resonance spectroscopy in chronic fatigue syndrome. Prostaglandins. Leukot. Essent. Fatty Acids 71, 181–3 (2004).
6.         Wong, R. et al. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest 102, 1716–22 (1992).
7.         Lane, R. J., Barrett, M. C., Taylor, D. J., Kemp, G. J. & Lodi, R. Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromuscul. Disord. 8, 204–9 (1998).
8.         McCully, K. K., Natelson, B. H., Iotti, S., Sisto, S. & Leigh, J. S. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve 19, 621–5 (1996).
9.         Lane, R. J. et al. Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. J. Neurol. Neurosurg. Psychiatry 64, 362–7 (1998).
10.       Vecchiet, L. et al. Sensory characterization of somatic parietal tissues in humans with chronic fatigue syndrome. Neurosci. Lett. 208, 117–20 (1996).
11.       Plioplys, A. V & Plioplys, S. Electron-microscopic investigation of muscle mitochondria in chronic fatigue syndrome. Neuropsychobiology 32, 175–81 (1995).
12.       Jammes, Y., Steinberg, J. G., Mambrini, O., Brégeon, F. & Delliaux, S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J. Intern. Med. 257, 299–310 (2005).
13.       Jammes, Y., Steinberg, J. G., Delliaux, S. & Brégeon, F. Chronic fatigue syndrome combines increased exercise-induced oxidative stress and reduced cytokine and Hsp responses. J. Intern. Med. 266, 196–206 (2009).
14.       Hollingsworth, K. G., Jones, D. E. J., Taylor, R., Blamire, A. M. & Newton, J. L. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur. J. Clin. Invest. 40, 608–15 (2010).
15.       Jones, D. E. J. et al. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. Eur. J. Clin. Invest. 42, 186–94 (2012).
16.       Myhill, S., Booth, N. E. & McLaren-Howard, J. Chronic fatigue syndrome and mitochondrial dysfunction. Int. J. Clin. Exp. Med. 2, 1–16 (2009).
17.       Myhill, S., Booth, N. E. & McLaren-Howard, J. Targeting mitochondrial dysfunction in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a clinical audit. Int. J. Clin. Exp. Med. 6, 1–15 (2013).
18.       Booth, N. E., Myhill, S. & McLaren-Howard, J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int. J. Clin. Exp. Med. 5, 208–20 (2012).
19.       Kaushik, N. et al. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J. Clin. Pathol. 58, 826–32 (2005).
20.       Vermeulen, R. C. W., Kurk, R. M., Visser, F. C., Sluiter, W. & Scholte, H. R. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J. Transl. Med. 8, 93 (2010).
21.       Castro-Marrero, J. et al. Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antioxid. Redox Signal. 19, 1855–60 (2013).
22.       Mathew, S. J. et al. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 22, 251–8 (2009).
23.       Murrough, J. W. et al. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 23, 643–50 (2010).
24.       Shungu, D. C. et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 25, 1073–87 (2012).
25.       Kuratsune, H. et al. Acylcarnitine deficiency in chronic fatigue syndrome. Clin. Infect. Dis. 18 Suppl 1, S62–7 (1994).
26.       Plioplys, A. V & Plioplys, S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 32, 132–8 (1995).
27.       Reuter, S. E. & Evans, A. M. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. J. Intern. Med. 270, 76–84 (2011).
28.       Li, Y.-J. et al. Clinical characteristics of patients with chronic fatigue syndrome: analysis of 82 cases. Zhonghua Yi Xue Za Zhi 85, 701–4 (2005).
29.       Kuratsune, H. et al. Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int. J. Mol. Med. 2, 51–6 (1998).
30.       Okada, T., Tanaka, M., Kuratsune, H., Watanabe, Y. & Sadato, N. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. BMC Neurol. 4, 14 (2004).
31.       Jones, M. G., Goodwin, C. S., Amjad, S. & Chalmers, R. A. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin. Chim. Acta. 360, 173–7 (2005).
32.       Soetekouw, P. M. et al. Normal carnitine levels in patients with chronic fatigue syndrome. Neth. J. Med. 57, 20–4 (2000).
33.       Kurup, R. K. & Kurup, P. A. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Int. J. Neurosci. 113, 683–701 (2003).
34.       Maes, M. et al. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol. Lett. 30, 470–6 (2009).
35.       Manuel y Keenoy, B. et al. Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. J. Am. Coll. Nutr. 19, 374–82 (2000).
36.       Vermeulen, R. C. W. & Scholte, H. R. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom. Med. 66, 276–82 (2004).
37.       Plioplys, A. V & Plioplys, S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology 35, 16–23 (1997).
38.       Santaella, M. L., Font, I. & Disdier, O. M. Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome. P. R. Health Sci. J. 23, 89–93 (2004).
39.       Forsyth, L. M. et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann. Allergy. Asthma Immunol. 82, 185–91 (1999).
40.       Alegre, J. et al. [Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome]. Rev. clínica española 210, 284–8 (2010).
41.       Teitelbaum, J. E., Johnson, C. & St Cyr, J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J. Altern. Complement. Med. 12, 857–62 (2006).
42.       Teitelbaum, J., Jandrain, J. & McGrew, R. Treatment of Chronic Fatigue Syndrome and Fibromyalgia with D-Ribose– An Open-label, Multicenter Study. Open Pain J. 32–37 (2012).
43.       Hokama, Y. et al. Anticardiolipin antibodies in the sera of patients with diagnosed chronic fatigue syndrome. J. Clin. Lab. Anal. 23, 210–2 (2009).
44.       Nicolson, G. L. & Ellithorpe, R. Lipid Replacement and Antioxidant Nutritional Therapy for Restoring Mitochondrial Function and Reducing Fatigue in Chronic Fatigue Syndrome and other Fatiguing Illnesses. J. Chronic Fatigue Syndr. 13, 57–68 (2006).
45.       White, A. T., Light, A. R., Hughen, R. W., Vanhaitsma, T. A. & Light, K. C. Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls. Psychosom. Med. 74, 46–54 (2012).
46.       Light, A. R. et al. Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. J. Intern. Med. 271, 64–81 (2012).
47.       Light, A. R., White, A. T., Hughen, R. W. & Light, K. C. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J. Pain 10, 1099–112 (2009).


  1. I like your blog, however there is no working RSS or Atom feed for your blog. The link that sasy "Subscribe to: Posts (Atom)" does not lead to a working feed

  2. I have chronic fatigue syndrome. I feel the line of the research goes a long way to explaining the symptoms I have had. What I want most of all is to recover. Do people recover? Does the mitochondrial dysfunction reverse or is it permanent?

    1. I certainly can't answer these questions definitively. There are some small reports in the scientific literature of people fully recovering in response to treatments, as well as some anecdotal stuff online. The bulk of people with CFS people probably improve at least a bit, whilst some more severe cases probably don't. This doesn't mean you can't improve significantly, its just that the condition isn't fully understood yet in the scientific community, even less so at the clinical level.

      CFS itself may consist of many different subgroups requiring different treatment. Mitochondrial dysfunction may occur for different reasons in each person. There is no evidence I am aware to suggest it is permanent, but it is far from being understood. Some aspects of mitochondrial dysfunction may be easy to fix however, like cofactor insufficiency. Mitochondrial membranes can be replace with NT factor. Toxin-adducts may need to be removed. Redox restored. Getting control of immune dysregulation and inflammation is likely crucial to most which means considering other things such as the gut and infections. There is a lot more research required to figure all this out.